PEACCEL is a DeepTech company pioneering AI- and Quantum-driven drug discovery. Its proprietary innov’SAR™ platform integrates generative AI, ML, DL, and early Quantum Machine Learning to engineer high-value biologics with exceptional speed and precision. The company targets two major unmet medical needs: (1) antimicrobial resistance, through first-in-class therapeutic peptides, and (2) cardio-metabolic disease, via a proprietary cholesterol-clearing peptide — both entering pre-clinical development. Powered by Google Cloud and supported by Synthelis (FR) for wet-lab validation, PEACCEL has secured $8.7M+ in non-dilutive funding, filed three global patent families, and demonstrated a quantum advantage up to 14 qubits over classical ML baselines. Recognized by NVIDIA as an “AI Start-Up to Watch, PEACCEL is now raising a $50 M Series A to expand its AI-Quantum discovery infrastructure and scale its peptide pipeline toward IND readiness.